# US 2010/0168156 A1 · Novel Benzoxathiine Derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168156 A1
- Document ID: US20100168156A1
- Status: Published application
- Kind: A1
- Application number: 12/084,017
- Filed: 2006-10-25
- Published: 2010-07-01
- Earliest claimed: 2005-10-27
- Assignees: Msd K. K.
- Inventors: Takashi Mizutani; Nagaaki Sato; Takahide Sasaki; Toshiyuki Takahashi
- Web page: https://patentgrep.com/patent/US20100168156A1

## CPC

- C07D 327/06: Six-membered rings
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 25/36: Opioid-abuse
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 497/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a compound represented by the formula (I) below and a pharmaceutically acceptable salt thereof. This compound is useful for treatment of obesity, diabetes and the like. [In the formula (I), Ar represents a benzene ring or the like; X1 represents a nitrogen atom, a sulfur atom or the like; R1 represents an aryl group or the like; X2 represents a group represented by the following formula (II): (wherein R4 and R5 respectively represent a lower alkyl group or the like, and m represents a number of 2-4) or the like; one of X and Y represents an oxygen atom and the other represents a sulfanyl group or the like; and X3-X6 respectively represent —CH—, a nitrogen atom or the like.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

A compound of the formula (I):
wherein:
R1 represents a hydrogen atom, a lower alkyl group (wherein the lower alkyl group may be substituted with a lower alkoxy group or a halogen atom), a lower alkoxy group (wherein the lower alkoxy group may be substituted with a halogen atom), an aryl group (wherein the aryl group may be substituted with a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), a lower alkoxy group (wherein the lower alkoxy group may be substituted with a halogen atom) or a halogen atom), or a heteroaryl group (wherein the heteroaryl group may be substituted with a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), a lower alkoxy group (wherein the lower alkoxy group may be substituted with a halogen atom), or a halogen atom);
R2 each independently represents a hydrogen atom, an amino group, an alkylamino group, a dialkylamino group, a nitro group, a cyano group, a hydroxyl group, a lower alkylsulfonyl group, a halogen atom, a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), a cycloalkyl group (wherein the cycloalkyl group may be substituted with a lower alkyl group or a halogen atom), a lower alkoxy group (wherein the lower alkoxy group may be substituted with a halogen atom), a cycloalkoxy group, an aryloxy group, an aralkyloxy group, a heteroaryloxy group, a heteroarylalkyloxy group, an aryl group, a heteroaryl group, an arylcarbamoyl group, a heteroarylcarbamoyl group, an aralkylcarbamoyl group, a heteroarylalkylcarbamoyl group, a mono or di-lower alkylcarbamoyl group, an aryloxycarbonylamino group, an aralkyloxycarbonylamino group, a lower alkoxycarbonylamino group, an alkanoylamino group, an arylcarbonylamino group, a heteroarylcarbonylamino group, an aralkylcarbonylamino group, a heteroarylalkylcarbonylamino group, an alkanoyl group, an arylcarbonyl group, an aralkylcarbonyl group, a formyl group, an alkylthio group, an alkylsulfonylamino group, an arylsulfonylamino group, a mono or di-lower alkylsulfamoyl group, an arylsulfamoyl group, or an aralkyl group;
one of X and Y is an oxygen atom, and the other is a sulfanyl group, a sulfinyl group or a sulfonyl group;
Ar represents a divalent group derived from a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring by removing two hydrogen atoms therefrom (wherein the divalent group may be substituted with a halogen atom, a lower alkoxy group (wherein the lower alkoxy group may be substituted with a halogen atom), a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), or a hydroxyl group);
X1 represents a carbon atom, a nitrogen atom, a sulfur atom or an oxygen atom;
X2 represents a group of a formula (II):
wherein R4 and R5 are the same or different, each representing a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), or a cycloalkyl group (wherein the cycloalkyl group may be substituted with a lower alkyl group or a halogen atom), or R4, R5 and the nitrogen atom to which they bond, taken together, form a 4- to 9-membered monocyclic ring or a 4- to 8-membered bicyclic ring (wherein the monocyclic ring or the bicyclic ring may be substituted with a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), a halogen atom, a hydroxyl group or an oxo group; and the monocyclic ring may have, in the ring, still another hetero atom selected from a nitrogen atom, a sulfur atom and an oxygen atom, in addition to the nitrogen atom to which R4 and R5 bond), m indicates from 2 to 4;
a group of a formula (III):
wherein R6 represents a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), or a cycloalkyl group (wherein the cycloalkyl group may be substituted with a lower alkyl group or a halogen atom), n indicates from 0 to 4,
or a group of a formula (IV):
X3 to X6 each independently represent —CR2— or a nitrogen atom; however, 3 or more of X3 to X6 are not nitrogen atoms at the same time;
the formula (V):
(V)
indicates a single bond or a double bond;
or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 25)

The compound of claim 25, wherein R2 each independently represents a hydrogen atom, a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), a halogen atom or a lower alkoxy group (wherein the lower alkoxy group may be substituted with a halogen atom).

### Claim 27 (depends on 25)

The compound of claim 25 of the formula (I-1):
wherein:
R1 represents a hydrogen atom, a lower alkyl group (wherein the lower alkyl group may be substituted with a lower alkoxy group or a halogen atom), a lower alkoxy group (wherein the lower alkoxy group may be substituted with a halogen atom), an aryl group (wherein the aryl group may be substituted with a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), a lower alkoxy group (wherein the lower alkoxy group may be substituted with a halogen atom) or a halogen atom), or a heteroaryl group (wherein the heteroaryl group may be substituted with a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), a lower alkoxy group (wherein the lower alkoxy group may be substituted with a halogen atom), or a halogen atom);
R2 each independently represents a hydrogen atom, a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), a lower alkoxy group (wherein the lower alkoxy group may be substituted with a halogen atom), or a halogen atom;
one of X and Y is an oxygen atom, and the other is a sulfanyl group, a sulfinyl group or a sulfonyl group;
Ar represents a divalent group derived from a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring by removing two hydrogen atoms therefrom (wherein the divalent group may be substituted with a halogen atom, a lower alkoxy group (wherein the lower alkoxy group may be substituted with a halogen atom), a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), or a hydroxyl group);
X1 represents a carbon atom, a nitrogen atom, a sulfur atom or an oxygen atom;
X2 represents a group of a formula (II):
wherein R4 and R5 are the same or different, each representing a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), or a cycloalkyl group (wherein the cycloalkyl group may be substituted with a lower alkyl group or a halogen atom), or R4, R5 and the nitrogen atom to which they bond, taken together, form a 4- to 9-membered monocyclic ring or a 4- to 8-membered bicyclic ring (wherein the monocyclic ring or the bicyclic ring may be substituted with a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), a halogen atom, a hydroxyl group or an oxo group; and the monocyclic ring may have, in the ring, still another hetero atom selected from a nitrogen atom, a sulfur atom and an oxygen atom, in addition to the nitrogen atom to which R4 and R5 bond), m indicates from 2 to 4;
a group of a formula (III):
wherein R6 represents a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), or a cycloalkyl group (wherein the cycloalkyl group may be substituted with a lower alkyl group or a halogen atom), n indicates from 0 to 4,
or a group of a formula (IV):
X3 to X6 each independently represent —CR2— or a nitrogen atom; however, 3 or more of X3 to X6 are not nitrogen atoms at the same time;
or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 27)

The compound of claim 27, wherein each of X3 to X6 are —CR2—.

### Claim 29 (depends on 27)

The compound of claim 27, wherein one of X3 to X6 is a nitrogen atom, and the remaining three are —CR2—.

### Claim 30 (depends on 27)

The compound of claim 27, wherein X2 is a group of the formula (II).

### Claim 31 (depends on 27)

The compound of claim 27, wherein X2 is a group of the formula (II); and
R4, R5 and the nitrogen atom to which they bond, taken together, form a pyrrolidine ring optionally substituted with a lower alkyl group, a piperidine ring optionally substituted with a lower alkyl group, an azepane ring optionally substituted with a lower alkyl group, or a azocane ring optionally substituted with a lower alkyl group; m is 3.

### Claim 32 (depends on 27)

The compound of claim 27, wherein X2 is a group of the formula (III).

### Claim 33 (depends on 27)

The compound of claim 27, wherein X2 is a group of the formula (III), R6 is a lower alkyl group or a cycloalkyl group, and n is 1 or 2.

### Claim 34 (depends on 27)

The compound of claim 27, wherein X is a sulfanyl group, a sulfinyl group or a sulfonyl group, and Y is an oxygen atom.

### Claim 35 (depends on 27)

The compound of claim 27, wherein X is an oxygen atom, and Y is a sulfanyl group, a sulfinyl group or a sulfonyl group.

### Claim 36 (depends on 27)

The compound of claim 27, wherein R1 is a hydrogen atom, a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), or a phenyl group.

### Claim 37

A compound which is selected from the group consisting of:
3-phenyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin,
3-phenyl-2-[4-[3-(1-piperidinyl)propoxy]phenyl]-1,4-benzoxathiin,
(2,3-cis)-2,3-dihydro-3-phenyl-2-[4-[3-(1-piperidinyl)propoxy]phenyl]-1,4-benzoxathiin,
(2,3-cis)-2,3-dihydro-3-phenyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin,
3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin,
3-ethyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin,
(2,3-cis)-2,3-dihydro-3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin,
(2,3-cis)-2,3-dihydro-3-ethyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin,
(2,3-cis)-2,3-dihydro-3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin-4,4-dioxide,
(2,3-cis)-2,3-dihydro-3-ethyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin-4,4-dioxide,
(2,3-trans)-2,3-dihydro-3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin,
(2,3-trans)-2,3-dihydro-3-ethyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin,
(2,3-trans)-2,3-dihydro-4,4-dioxido-3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin,
(2,3-trans)-2,3-dihydro-3-ethyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin-4,4-dioxide,
(2,3-cis)-2,3-dihydro-3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin-4-oxide,
(2,3-cis)-2,3-dihydro-3-ethyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin-4-oxide,
(2,3-cis)-2,3-dihydro-2-methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin,
(2,3-cis)-2,3-dihydro-2-methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin-4,4-dioxide,
2,3-dihydro-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin,
(2,3-trans)-2,3-dihydro-3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin-4-oxide,
(2,3-trans)-2,3-dihydro-3-ethyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin-4-oxide,
(2,3-trans)-2,3-dihydro-3-ethyl-2-[4-[3-((3S)-3-methyl-1-piperidinyl)propoxy]phenyl]-1,4-benzoxathiin,
(2,3-trans)-2,3-dihydro-3-ethyl-2-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-1,4-benzoxathiin,
(2,3-trans)-2,3-dihydro-3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-[1,4]oxathiino[3,2-b]pyridine,
(2,3-trans)-2,3-dihydro-3-ethyl-2-[4-[3-((3S)-3-methyl-1-piperidinyl)propoxy]phenyl]-1,4-benzoxathiin-4,4-dioxide,
(2,3-trans)-2,3-dihydro-3-ethyl-2-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-1,4-benzoxathiin-4,4-dioxide,
(2S,3S)-2,3-dihydro-3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin-4,4-dioxide,
(2R,3R)-2,3-dihydro-3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1,4-benzoxathiin-4,4-dioxide,
(2,3-trans)-2,3-dihydro-3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-[1,4]oxathiino[3,2-b]pyridine-4,4-dioxide,
(2,3-trans)-2,3-dihydro-3-methyl-2-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-1,4-benzoxathiin-4,4-dioxide,
(2,3-trans)-2,3-dihydro-3-methyl-2-[4-[3-((3S)-3-methyl-1-piperidinyl)propoxy]phenyl]-1,4-benzoxathiin-4,4-dioxide,
(2,3-trans)-2,3-dihydro-8-methoxy-3-methyl-2-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-1,4-benzoxathiin-4,4-dioxide,
1-[3-[4-[(2,3-trans)-2,3-dihydro-4,4-dioxido-8-methoxy-3-methyl-1,4-benzoxathiin-2-yl]phenoxy]propyl]-(3S)-3-methylpiperidine,
1-[3-[4-[(2,3-trans)-2,3-dihydro-4,4-dioxido-8-methoxy-3-methyl-1,4-benzoxathiin-2-yl]phenoxy]propyl]-pyrrolidine,
1-[3-[4-[(2,3-trans)-2,3-dihydro-4,4-dioxido-8-methoxy-3-methyl-1,4-benzoxathiin-2-yl]phenoxy]propyl]-piperidine,
1-[3-[4-[(2,3-trans)-2,3-dihydro-4,4-dioxido-5-methoxy-3-methyl-1,4-benzoxathiin-2-yl]phenoxy]propyl]-pyrrolidine,
1-[3-[4-[(2,3-trans)-2,3-dihydro-4,4-dioxido-5-methoxy-3-methyl-1,4-benzoxathiin-2-yl]phenoxy]propyl]-piperidine,
1-[3-[5-[(2,3-trans)-2,3-dihydro-4,4-dioxido-3-methyl-1,4-benzoxathiin-2-yl]pyridin-2-yloxy]propyl-pyrrolidine,
1-[3-[4-[(2,3-trans)-2,3-dihydro-4,4-dioxido-6-methoxy-3-methyl-1,4-benzoxathiin-2-yl]phenoxy]propyl]-pyrrolidine,
1-[3-[4-[(2,3-trans)-2,3-dihydro-4,4-dioxido-6-methoxy-3-methyl-1,4-benzoxathiin-2-yl]phenoxy]propyl]-piperidine,
1-[3-[4-[(2S,3S)-2,3-dihydro-4,4-dioxido-8-methoxy-3-methyl-1,4-benzoxathiin-2-yl]phenoxy]propyl]-pyrrolidine,
1-[3-[4-[(2R,3R)-2,3-dihydro-4,4-dioxido-8-methoxy-3-methyl-1,4-benzoxathiin-2-yl]phenoxy]propyl]-pyrrolidine,
(2S,3S)-2,3-dihydro-8-methoxy-3-methyl-2-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-1,4-benzoxathiin-4,4-dioxide,
(2R,3R)-2,3-dihydro-8-methoxy-3-methyl-2-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-1,4-benzoxathiin-4,4-dioxide,
1-[3-[4-[(2,3-trans)-2,3-dihydro-4,4-dioxido-7-methoxy-3-methyl-1,4-benzoxathiin-2-yl]phenoxy]propyl]-pyrrolidine,
1-[3-[4-[(2,3-trans)-2,3-dihydro-4,4-dioxido-7-methoxy-3-methyl-1,4-benzoxathiin-2-yl]phenoxy]propyl]-piperidine,
1-[3-[4-[(2,3-trans)-2,3-dihydro-4,4-dioxido-3-methyl-[1,4]oxathiino[3,2-b]pyridin-2-yl]phenoxy]propyl]-piperidine,
(2,3-trans)-2,3-dihydro-5-methoxy-3-methyl-2-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-1,4-benzoxathiin-4,4-dioxide,
(2S,3S)-2,3-dihydro-5-methoxy-3-methyl-2-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-1,4-benzoxathiin-4,4-dioxide,
(2R,3R)-2,3-dihydro-5-methoxy-3-methyl-2-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-1,4-benzoxathiin-4,4-dioxide,
(2S,3S)-2,3-dihydro-3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-[1,4]oxathiino[3,2-b]pyridin-4,4-dioxide,
(2R,3R)-2,3-dihydro-3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-[1,4]oxathiino[3,2-b]pyridin-4,4-dioxide,
1-[3-[4-[(2S,3S)-2,3-dihydro-4,4-dioxido-5-methoxy-3-methyl-1,4-benzoxathiin-2-yl]phenoxy]propyl]-piperidine,
1-[3-[4-[(2R,3R)-2,3-dihydro-4,4-dioxido-5-methoxy-3-methyl-1,4-benzoxathiin-2-yl]phenoxy]propyl]-piperidine,
(2R,3R)-2-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-3-methyl-2,3-dihydro[1,4]oxathiino[3,2-b]pyridine 4,4-dioxide,
(2S,3S)-2-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-3-methyl-2,3-dihydro[1,4]oxathiino[3,2-b]pyridine 4,4-dioxide,
1-[3-[4-[(2S,3S)-2,3-dihydro-4,4-dioxido-3-methyl-[1,4]oxathiino[3,2-b]pyridin-2-yl]phenoxy]propyl]-piperidine,
1-[3-[4-[(2R,3R)-2,3-dihydro-4,4-dioxido-3-methyl-[1,4]oxathiino[3,2-b]pyridin-2-yl]phenoxy]propyl]-piperidine,
(2S,3S)-3-methyl-2-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-2,3-dihydro[1,4]oxathiino[3,2-b]pyridine 4,4-dioxide,
(2R,3R)-3-methyl-2-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-2,3-dihydro[1,4]oxathiino[3,2-b]pyridine 4,4-dioxide,
(2S,3S)-2-{4-[(1-isopropylpiperidin-4-yl)oxy]phenyl}-3-methyl-2,3-dihydro[1,4]oxathiino[3,2-b]pyridine 4,4-dioxide,
(2R,3R)-2-{4-[(1-isopropylpiperidin-4-yl)oxy]phenyl}-3-methyl-2,3-dihydro[1,4]oxathiino[3,2-b]pyridine 4,4-dioxide,
(2S*,3S*)-2-[3-bromo-4-(3-pyrrolidin-1-ylpropoxy)phenyl]-3-methyl-2,3-dihydro[1,4]oxathiino[3,2-b]pyridine 4,4-dioxide,
1-(3-{2-bromo-4-[(2S*,3S*)-8-methoxy-3-methyl-4,4-dioxido-2,3-dihydro-1,4-benzoxathiin-2-yl]phenoxy}propyl)pyrrolidine,
1-{3-[4-(3-methyl-4,4-dioxido-1,4-benzoxathiin-2-yl)phenoxy]propyl}pyrrolidine,
1-{2-[4-(3-phenyl-1,4-benzoxathiin-2-yl)phenoxy]ethyl}pyrrolidine,
1-(2-{4-[(2,3-cis)-3-phenyl-2,3-dihydro-1,4-benzoxathiin-2-yl]phenoxy}ethyl)pyrrolidine,
1-{2-[4-(3-phenyl-1,4-benzoxathiin-2-yl)phenoxy]ethyl}piperidine, and
1-(2-{4-[(2,3-cis)-3-phenyl-2,3-dihydro-1,4-benzoxathiin-2-yl]phenoxy}ethyl)piperidine,
or a pharmaceutically acceptable salt thereof.

### Claim 38 (depends on 37)

The compound of claim 37 which is selected from the group consisting of:
1-[3-[4-[(2S,3S)-2,3-dihydro-4,4-dioxido-8-methoxy-3-methyl-1,4-benzoxathiin-2-yl]phenoxy]propyl]-pyrrolidine; and
1-[3-[4-[(2R,3R)-2,3-dihydro-4,4-dioxido-8-methoxy-3-methyl-1,4-benzoxathiin-2-yl]phenoxy]propyl]-pyrrolidine;
or a pharmaceutically acceptable salt thereof.

### Claim 39 (depends on 37)

The compound of claim 37 which is selected from the group consisting of:
(2R,3R)-2,3-dihydro-8-methoxy-3-methyl-2-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-1,4-benzoxathiin-4,4-dioxide; and
(2S,3S)-2,3-dihydro-8-methoxy-3-methyl-2-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-1,4-benzoxathiin-4,4-dioxide;
or a pharmaceutically acceptable salt thereof.

### Claim 40 (depends on 37)

The compound of claim 37 which is selected from the group consisting of:
(2S,3S)-2,3-dihydro-3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-[1,4]oxathiino[3,2-b]pyridine-4,4-dioxide; and
(2R,3R)-2,3-dihydro-3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-[1,4]oxathiino[3,2-b]pyridine-4,4-dioxide;
or a pharmaceutically acceptable salt thereof.

### Claim 41 (depends on 37)

The compound of claim 37 which is selected from the group consisting of:
(2R,3R)-2-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-3-methyl-2,3-dihydro[1,4]oxathiino[3,2-b]pyridine 4,4-dioxide; and
(2S,3S)-2-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-3-methyl-2,3-dihydro[1,4]oxathiino[3,2-b]pyridine 4,4-dioxide;
or a pharmaceutically acceptable salt thereof.

### Claim 42 (depends on 37)

The compound of claim 37 which is selected from the group consisting of:
(2S,3S)-3-methyl-2-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-2,3-dihydro[1,4]oxathiino[3,2-b]pyridine 4,4-dioxide; and
(2R,3R)-3-methyl-2-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-2,3-dihydro[1,4]oxathiino[3,2-b]pyridine 4,4-dioxide;
or a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 25)

A pharmaceutical composition which comprises a pharmaceutically acceptable additive and the compound of claim 25 or a pharmaceutical acceptable salt

### Claim 44 (depends on 25)

A method for the treatment of a disease or disorder selected from a metabolic system disease, obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, a circulatory system disease, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, electrolyte disorder, a sleep disorder, a disease accompanied by sleep disorder, idiopathic hypersomnnia, repetitive hypersomnnia, true hypersomnnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night workers' sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, a central nervous system disease, a peripheral nervous system disease, bulimia, emotional disorder, depression, anxiety, delirium, dementia, schizophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, cognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, drug dependency and alcoholism, in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 25 or a pharmaceutically acceptable salt thereof.
